<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Cheminform</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Cheminform</journal-id>
    <journal-title-group>
      <journal-title>Journal of Cheminformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-2946</issn>
    <publisher>
      <publisher-name>Springer International Publishing</publisher-name>
      <publisher-loc>Cham</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7656723</article-id>
    <article-id pub-id-type="publisher-id">471</article-id>
    <article-id pub-id-type="doi">10.1186/s13321-020-00471-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>LigGrep: a tool for filtering docked poses to improve virtual-screening hit rates</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Ha</surname>
          <given-names>Emily J.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lwin</surname>
          <given-names>Cara T.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5808-4097</contrib-id>
        <name>
          <surname>Durrant</surname>
          <given-names>Jacob D.</given-names>
        </name>
        <address>
          <email>durrantj@pitt.edu</email>
        </address>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.147455.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 0344</institution-id><institution>Department of Biological Sciences, </institution><institution>Carnegie Mellon University, </institution></institution-wrap>Pittsburgh, PA 15213 United States </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>Department of Biological Sciences, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA 15260 United States </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>11</day>
      <month>11</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>11</day>
      <month>11</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>69</elocation-id>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>7</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>19</day>
        <month>10</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Structure-based virtual screening (VS) uses computer docking to prioritize candidate small-molecule ligands for subsequent experimental testing. Docking programs evaluate molecular binding in part by predicting the geometry with which a given compound might bind a target receptor (e.g., the docked “pose” relative to a protein target). Candidate ligands predicted to participate in the same intermolecular interactions typical of known ligands (or ligands that bind related proteins) are arguably more likely to be true binders. Some docking programs allow users to apply constraints during the docking process with the goal of prioritizing these critical interactions. But these programs often have restrictive and/or expensive licenses, and many popular open-source docking programs (e.g., AutoDock Vina) lack this important functionality. We present LigGrep, a free, open-source program that addresses this limitation. As input, LigGrep accepts a protein receptor file, a directory containing many docked-compound files, and a list of user-specified filters describing critical receptor/ligand interactions. LigGrep evaluates each docked pose and outputs the names of the compounds with poses that pass all filters. To demonstrate utility, we show that LigGrep can improve the hit rates of test VS targeting <italic>H. sapiens</italic> poly(ADPribose) polymerase 1 (<italic>Hs</italic>PARP1), <italic>H. sapiens</italic> peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (<italic>Hs</italic>Pin1p), and <italic>S. cerevisiae</italic> hexokinase-2 (<italic>Sc</italic>Hxk2p). We hope that LigGrep will be a useful tool for the computational biology community. A copy is available free of charge at <ext-link ext-link-type="uri" xlink:href="http://durrantlab.com/liggrep/">http://durrantlab.com/liggrep/</ext-link>.</p>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Virtual screening</kwd>
      <kwd>Computer-aided drug discovery</kwd>
      <kwd>Computational biology</kwd>
      <kwd>Filters</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id>
            <institution>National Institute of General Medical Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R01GM132353</award-id>
        <principal-award-recipient>
          <name>
            <surname>Lwin</surname>
            <given-names>Cara T.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2020</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">Traditional high-throughput screening (HTS) is a powerful experimental technique for identifying molecules that can be further developed into novel pharmaceutics. It involves screening a large number of compounds against selected disease targets (e.g., disease-relevant proteins) to find compounds (i.e., “hits”) that elicit measurable biological or biophysical responses. HTS does not require any prior knowledge of the drug-target structure. But the associated hit rates are often low, and it is costly to experimentally test so many molecules. HTS is thus limited primarily to research groups working in the pharmaceutical industry [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par3">Computer-aided drug discovery (CADD) aims to address some of these challenges. Among CADD techniques, structure-based virtual screening (VS) is particularly popular. VS draws on a library of virtual small molecules and a model of the drug target. A docking program first predicts how each molecule physically interacts with the target protein, often by binding to a pocket on the target surface [<xref ref-type="bibr" rid="CR2">2</xref>]. The geometry of the bound molecule relative to the target structure is called the docked pose. Based on this pose, the docking program then estimates the strength of binding (the docking score) using a pre-determined scoring function [<xref ref-type="bibr" rid="CR3">3</xref>]. The set of compounds with reasonable docked poses and good docking scores is often enriched with true binders. These candidate ligands are then prioritized for subsequent experimental testing [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. This targeted-search approach reduces cost, preparation time, and workload relative to HTS.</p>
    <p id="Par4">Assessing candidate ligands by docking score is straightforward, but assessing predicted poses is often more subjective and time consuming. One objective pose-assessment approach is to search for new molecules that are predicted to participate in the same critical interactions with the drug target that are typical of known ligands. For example, all clinically approved inhibitors of influenza neuraminidase interact with certain key arginine residues [<xref ref-type="bibr" rid="CR5">5</xref>], so docked compounds that are not predicted to participate in those interactions might be discarded regardless of score. Unfortunately, in the case of large-scale VS there may be many thousands (or even millions) of docked poses, complicating comprehensive manual inspection.</p>
    <p id="Par5">To automate pose assessment, some commercial docking programs (e.g., Schrödinger’s Glide and OpenEye’s FRED) automatically reject poses that do not satisfy user-specified filters. These programs are powerful, but they have restrictive and/or expensive licenses that make them inaccessible to many groups. Even OpenEye’s free academic license imposes substantial commercialization and intellectual-property restrictions. In contrast, many popular open-source docking programs (e.g., AutoDock Vina [<xref ref-type="bibr" rid="CR6">6</xref>]) have far more permissive licenses, but they often lack a pose-filtering step.</p>
    <p id="Par6">To address this limitation, we have created LigGrep, a free, open-source program that filters predicted ligand poses that were previously generated during a VS campaign. LigGrep analyzes the pose of each docked compound and discards those poses that do not participate in user-specified interactions. Alternatively, it can also discard poses that involve unfavorable interactions (e.g., interactions with residues known to be involved in resistance mechanisms). LigGrep will help improve VS hit rates by allowing the community to focus on high-scoring compounds that also satisfy carefully chosen binding-pose criteria. A copy is available at <ext-link ext-link-type="uri" xlink:href="http://durrantlab.com/liggrep/">http://durrantlab.com/liggrep/</ext-link>, released under the terms of the Apache License, Version 2.0.</p>
  </sec>
  <sec id="Sec2">
    <title>Implementation</title>
    <sec id="Sec3">
      <title>The LigGrep algorithm</title>
      <p id="Par7">LigGrep accepts as input (1) a PDBQT or PDB file of the drug-target receptor used for docking, (2) a directory of PDBQT, PDB, or SDF files containing the docked poses of candidate ligands, and (3) a JSON-formatted file describing user-specified filters. After evaluating each docked pose, it outputs the names of any compounds with poses that satisfy all user-defined filters. The following sections describe each of these steps in detail.</p>
      <sec id="Sec4">
        <title>Input receptor molecule</title>
        <p id="Par8">LigGrep’s first command-line argument is the path to the PDB/PDBQT-formatted receptor file used for docking. LigGrep uses the Scoria Python library [<xref ref-type="bibr" rid="CR7">7</xref>] to load the receptor file. Because Scoria is a pure-Python library with a permissive license, we package a copy together with LigGrep itself for convenience.</p>
      </sec>
      <sec id="Sec5">
        <title>Input ligand molecules</title>
        <p id="Par9">LigGrep’s second command-line argument is the path to a directory containing the docked-compound files. To accommodate a broad range of docking programs, we designed LigGrep to accept docked poses in three popular file formats. These include the PDBQT format to accommodate docking programs such as AutoDock Vina [<xref ref-type="bibr" rid="CR6">6</xref>], the PDB format to accommodate big-data studies of crystallographic poses, and the SDF format to accommodate programs such as Schrödinger’s Glide. Researchers who wish to examine predicted or experimentally determined poses saved in other formats can convert to the SDF format using open-source programs such as Open Babel [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p id="Par10">In many cases, users will wish to filter poses by considering only a single ligand atom (e.g., “which poses place an oxygen atom in a particular region of the binding pocket?”). In other cases, users may wish to filter poses using more complex ligand substructures (e.g., “which poses place a hydroxyl group in a particular region?”). In still other cases, substructures with specific atomic-bond specifications may be critical (e.g., “which poses place a phenyl group–but not a cyclohexyl group–in a particular region?”). Users can run LigGrep in three modes (NONE, OPENBABEL, and SMILES) according to their needs.</p>
        <p id="Par11"><bold>NONE mode</bold>. In NONE mode (<italic>--mode NONE</italic>), LigGrep does not assign bond orders beyond those described in the docked-compound files themselves. In the case of PDB/PDBQT files, which do not include any information about bond orders, LigGrep assumes that all atoms are sp<sup>3</sup> hybridized and that all appropriately juxtaposed atoms are connected by single bonds. In the case of SDF files, which do include detailed information about atomic bonds, LigGrep instead assigns bond orders based on the information present in the SDF files themselves. NONE mode is thus ideal when (1) filtering by a single atom, (2) filtering by a substructure whose atoms are connected only by single bonds, or (3) applying filters of any type to SDF-formatted docked poses.</p>
        <p id="Par12"><bold>SMILES mode</bold>. In SMILES mode (<italic>--mode SMILES</italic>), LigGrep assigns bond orders to PDB/PDBQT-formatted docked-compound files by additionally considering user-specified files in the SMILES format. The simplified molecular-input line-entry system (SMILES) format is a widely used, compact format that encodes a molecule’s connectivity and chirality as a simple, one-line string of letters and other symbols. To run LigGrep in SMILES mode, the user should save a separate SMILES file for each PDB/PDBQT-formatted docked compound, in the same compound directory. Each SMILES file should have the same filename as the corresponding PDB/PDBQT file, plus the “.smi” extension. SMILES mode is ideal when (1) SMILES strings are available or can be easily generated, (2) filters involve substructures with higher-order (e.g., double, triple, aromatic) bonds, and (3) the docked files are PDB/PDBQT formatted. SMILES mode is not appropriate for SDF-formatted files because these already include bond-order information.</p>
        <p id="Par13"><bold>OPENBABEL mode</bold>.  In OPENBABEL mode (<italic>--mode OPENBABEL</italic>), LigGrep uses the Open Babel (<italic>obabel</italic>) executable [<xref ref-type="bibr" rid="CR8">8</xref>] to try to assign atom hybridization and bond orders to docked-compound PDB/PDBQT files. Users must specify the path to the Open Babel executable using LigGrep’s <italic>--babel_exec /PATH/TO/OBABEL</italic> parameter. Internally, Open Babel converts PDB/PDBQT files to the SDF format, which includes bond-order information that the Python library RDKit [<xref ref-type="bibr" rid="CR9">9</xref>] can then process. Unfortunately, PDBQT files do not include non-polar hydrogen atoms, complicating this process. LigGrep runs Open Babel first using the <italic>−h</italic> option to add all missing hydrogen atoms. If that hydrogen-atom assignment does not match the atoms present in the input PDB/PDBQT file, LigGrep reruns Open Babel using the <italic>−p</italic> option, which adds hydrogen atoms as appropriate for neutral pH (7.4). If this second attempt fails, LigGrep issues a warning and moves on to the next docked-compound file.</p>
        <p id="Par14">We provide OPENBABEL mode for user convenience. It allows users to process PDB/PDBQT-formatted poses using higher-order substructure filters, even when SMILES strings are not available. But we recommend using OPENBABEL mode cautiously. Given the ambiguities associated with assigning hybridization and bond orders based on atomic coordinates alone, LigGrep in OPENBABEL mode may misclassify some compounds. Furthermore, OPENBABEL mode is not appropriate when filtering SDF-formatted poses because SDF files already include bond-order information.</p>
      </sec>
      <sec id="Sec6">
        <title>Input-filters file</title>
        <p id="Par15">LigGrep’s third command-line argument is the path to a JSON file containing a list of filters that the input compounds must satisfy (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). LigGrep filters have four user-defined components: (1) a ligand-substructure specification describing one or more bonded atoms, (2) a point in 3D space (the query point), (3) a distance cutoff, and (4) an optional “exclude” flag.<fig id="Fig1"><label>Fig. 1</label><caption><p>Sample JSON file containing hypothetical filters. Filter #1 shows a 3D query point specified by a receptor atom. Filter #2 shows a 3D query point specified by a coordinate, with the exclude flag set</p></caption><graphic xlink:href="13321_2020_471_Fig1_HTML" id="MO1"/></fig></p>
        <p id="Par16"><bold>Identifying ligand substructures</bold>. To determine whether a given docked pose satisfies the user-specified filters list, LigGrep first uses the RDKit Python library [<xref ref-type="bibr" rid="CR9">9</xref>] to check whether the molecule contains the necessary substructures (i.e., the substructures associated with all filters that do not have “exclude” flags, Fig. <xref rid="Fig1" ref-type="fig">1</xref>a). LigGrep rejects all molecules that do not contain each of the necessary substructures. Users specify substructures via SMILES arbitrary target specification (SMARTS) notation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a and d), which is syntactically similar to SMILES. When using LigGrep in <italic>NONE</italic> mode to filter PDB/PDBQT-formatted docked molecules, substructures must include only sp<sup>3</sup>-hybridized atoms connected by single bonds (as in Fig. <xref rid="Fig1" ref-type="fig">1</xref>a). Otherwise, the SMARTS strings can include more complex substructure descriptions (e.g., aromatic rings, as in Fig. <xref rid="Fig1" ref-type="fig">1</xref>d).</p>
        <p id="Par17"><bold>Identifying the 3D query point</bold>. For each specified filter, LigGrep identifies the appropriate 3D query point by examining the corresponding JSON data. If the filter JSON contains the key “coordinate”, LigGrep constructs the 3D query point directly from the corresponding value, a list containing x, y, and z coordinates (Fig. <xref rid="Fig1" ref-type="fig">1</xref>e). If the filter JSON contains the key “receptorAtom”, LigGrep constructs the 3D query point by searching the input receptor file for an atom that matches the provided chain, residue id (resid), and atom name (atomname) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). The 3D query point is then set to the coordinate of that atom.</p>
        <p id="Par18"><bold>Accepting or rejecting docked compounds based on atomic distances</bold>. Once LigGrep has identified the relevant small-molecule substructures and 3D query points, it determines whether a given docked pose passes or fails each filter. If it passes all filters, the name of the compound file is saved to an output text file. If it fails any of the filters, the compound file name is not saved. The filters are thus combined using a Boolean AND (conjunction) operator, though advanced users familiar with SMARTS notation can also embed additional logical operators within their substructure specifications for more complex, nested logic.</p>
        <p id="Par19">To apply each filter, LigGrep first calculates the minimum distance between any small-molecule-substructure atom and the corresponding 3D query point. It then compares this calculated distance to the cutoff distance associated with each filter (Fig. <xref rid="Fig1" ref-type="fig">1</xref>c). By default, a given docked pose passes a filter if it positions the substructure near the query point. If the user includes an optional “exclude” flag (Fig. <xref rid="Fig1" ref-type="fig">1</xref>f), a pose passes only if it does not position the substructure near the query point. The specific criteria used to assess each filter are given in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>LigGrep criteria for assessing user-defined filters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Has substructure</th><th align="left">Exclude flag set</th><th align="left">Any substructure atom within cutoff distance</th><th align="left">Result</th></tr></thead><tbody><tr><td align="left">No</td><td align="left">No</td><td align="left">N/a</td><td align="left">Fail</td></tr><tr><td align="left">No</td><td align="left">Yes</td><td align="left">N/a</td><td align="left">Pass</td></tr><tr><td align="left">Yes</td><td align="left">No</td><td align="left">No</td><td align="left">Fail</td></tr><tr><td align="left">Yes</td><td align="left">No</td><td align="left">Yes</td><td align="left">Pass</td></tr><tr><td align="left">Yes</td><td align="left">Yes</td><td align="left">No</td><td align="left">Pass</td></tr><tr><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Fail</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Dependencies and compatibility</title>
      <p id="Par20">We have tested LigGrep on macOS, Ubuntu Linux, and Windows 10 (Table <xref rid="Tab2" ref-type="table">2</xref>). LigGrep requires the third-party Python libraries RDKit [<xref ref-type="bibr" rid="CR9">9</xref>], NumPy [<xref ref-type="bibr" rid="CR10">10</xref>], and SciPy [<xref ref-type="bibr" rid="CR11">11</xref>], which must be installed separately. It comes pre-packaged with the Scoria library [<xref ref-type="bibr" rid="CR7">7</xref>] for convenience. When running LigGrep in the preferred NONE or SMILES mode, the Open Babel executable is not required. Users who wish to use OPENBABEL mode must install Open Babel separately.<table-wrap id="Tab2"><label>Table 2</label><caption><p>We have tested LigGrep on various operating systems, using various versions of Python 3, RDKit, NumPy, SciPy, and Open Babel</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Operating system</th><th align="left">Python</th><th align="left">RDKit</th><th align="left">NumPy</th><th align="left">SciPy</th><th align="left">Open babel</th><th align="left">Multiprocessing</th></tr></thead><tbody><tr><td align="left">macOS Mojave 10.14.5</td><td align="left">3.6.7</td><td align="left">2019.03.3</td><td align="left">1.17.4</td><td align="left">1.3.1</td><td align="left">2.4.1</td><td align="left">Y</td></tr><tr><td align="left">Ubuntu 18.04.4 LTS</td><td align="left">3.6.5</td><td align="left">2019.03.1</td><td align="left">1.16.3</td><td align="left">1.3.0</td><td align="left">3.1.0</td><td align="left">Y</td></tr><tr><td align="left">Ubuntu 18.04.2 LTS</td><td align="left">3.7.3</td><td align="left">2020.03.3</td><td align="left">1.18.1</td><td align="left">1.4.1</td><td align="left">2.3.2</td><td align="left">Y</td></tr><tr><td align="left">Windows 10 Home 1903</td><td align="left">3.7.4</td><td align="left">2020.03.2</td><td align="left">1.16.5</td><td align="left">1.3.1</td><td align="left">2.3.1</td><td align="left">N</td></tr></tbody></table><table-wrap-foot><p>Multiprocessing is not supported on Windows. Note that LigGrep is designed to work with Python 3, not Python 2</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec8">
      <title>Benchmark virtual screens</title>
      <sec id="Sec9">
        <title>Preparing the receptors</title>
        <p id="Par21">To demonstrate LigGrep use, we performed VS against three proteins: <italic>H. sapiens</italic> poly(ADP-ribose) polymerase 1 (<italic>Hs</italic>PARP1), <italic>H. sapiens</italic> peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (<italic>Hs</italic>Pin1p), and <italic>S. cerevisiae</italic> hexokinase-2 (<italic>Sc</italic>Hxk2p). We downloaded <italic>Hs</italic>PARP1, <italic>Hs</italic>Pin1p, and <italic>Sc</italic>Hxk2p crystal structures (6BHV [<xref ref-type="bibr" rid="CR12">12</xref>], 3TDB [<xref ref-type="bibr" rid="CR13">13</xref>], and 1IG8 [<xref ref-type="bibr" rid="CR14">14</xref>], respectively) from the RCSB Protein Data Bank [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. We selected the 6BHV <italic>Hs</italic>PARP1 structure because its co-crystallized ligand, benzamide adenine nucleotide, was the largest by mass of 46 co-crystallized ligands considered (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1), and some studies suggest that larger binding-pocket conformations are more amenable to VS [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. We selected the 3TDB <italic>Hs</italic>Pin1p structure because its co-crystallized ligand was the largest by mass of 27 considered (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Finally, we selected the 1IG8 <italic>Sc</italic>Hxk2p structure because it is the only <italic>Sc</italic>Hxk2p structure with the correct amino-acid sequence. In all cases, we used the PDB2PQR server [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>] to add hydrogen atoms to these protein structures and to optimize their hydrogen-bond networks (default parameters, pH 7). We then used Open Babel [<xref ref-type="bibr" rid="CR8">8</xref>] to convert the resulting protonated PQR files to the PDB format. Finally, we used MGLTools 1.5.6 [<xref ref-type="bibr" rid="CR22">22</xref>] to convert the PDB files to the PDBQT format, which includes atom types and partial atomic charges.</p>
      </sec>
      <sec id="Sec10">
        <title>Preparing the small-molecule libraries</title>
        <p id="Par22">To prepare a library of small molecules for <italic>Hs</italic>PARP1 docking, we downloaded the SMILES strings of 46 known <italic>Hs</italic>PARP1 ligands (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) and 1515 diverse small molecules (presumed decoys). The known ligands were taken from <italic>Hs</italic>PARP1 crystal structures deposited in the RCSB Protein Data Bank, and the decoys were taken from the NCI Diversity Set VI, a set of freely available compounds provided by the National Cancer Institute (NCI) [<xref ref-type="bibr" rid="CR23">23</xref>]. We created a similar small-molecule library of known ligands and NCI decoys for <italic>Hs</italic>Pin1p docking, using 27 co-crystallized <italic>Hs</italic>Pin1p ligands (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). For <italic>Sc</italic>Hxk2p docking, we identified 41 glucose analogues known to bind hexokinase and glucokinase proteins from various species (presumed <italic>Sc</italic>Hxk2p ligands; eight from the RCSB Protein Data Bank, and 33 from the BindingDB database [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). As <italic>Sc</italic>Hxk2p decoys, we selected 1652 glucose analogues with molecular weights less than 500 Daltons, taken from the ChemDiv and eMolecules databases (presumed inactives).</p>
        <p id="Par23">We used the open-source program Gypsum-DL [<xref ref-type="bibr" rid="CR4">4</xref>] to generate 3D small-molecule models from these SMILES strings. To account for alternate ionization, tautomeric, chiral, isomeric, and ring-conformational forms, we instructed Gypsum-DL to generate two molecular variants per input compound (<italic>min_ph</italic>: 7.4; <italic>max_ph</italic>: 7.4; <italic>pka_precision</italic>: 0). We also used Gypsum-DL’s <italic>--use_durrant_lab_filters</italic> flag to remove molecular variants judged improbable. The output small-molecule PDB files were again converted to the PDBQT format using MGLTools 1.5.6 [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
      </sec>
      <sec id="Sec11">
        <title>Docking</title>
        <p id="Par24">To prepare for docking, we used AutoDockTools [<xref ref-type="bibr" rid="CR22">22</xref>] and Webina [<xref ref-type="bibr" rid="CR26">26</xref>] to identify a docking box centered on the ligand-binding pockets of the respective crystal structures. In the case of the 6BHV <italic>Hs</italic>PARP1 structure, we retained all four catalytic domains present in the 6BHV asymmetric unit for simplicity’s sake, but the docking box (23 Å x 17 Å x 20 Å) encompassed only chain-A atoms. The <italic>Hs</italic>Pin1p and <italic>Sc</italic>Hxk2p docking boxes were 20 Å x 20 Å x 20 Å and 20 Å x 19 Å x 15 Å, respectively. We docked all compounds into their respective receptors using AutoDock Vina [<xref ref-type="bibr" rid="CR6">6</xref>], with Vina’s default parameters.</p>
      </sec>
      <sec id="Sec12">
        <title>Defining LigGrep filters</title>
        <p id="Par25">To construct LigGrep filters suitable for the HsPARP1 VS,PARP1 VS, we reviewed a recently published table of predicted <italic>Hs</italic>PARP1/ligand interactions that were frequently identified in a large-scale de novo CADD campaign [<xref ref-type="bibr" rid="CR27">27</xref>]. Two of the most frequent interactions were also observed in crystal structures of <italic>Hs</italic>PARP1 bound to the clinically approved inhibitor niraparib (4R6E:A [<xref ref-type="bibr" rid="CR28">28</xref>]) and a 4(3<italic>H</italic>)-quinazolinone derivative (1UK0:A [<xref ref-type="bibr" rid="CR29">29</xref>]): a hydrogen bond with G863, and a <inline-formula id="IEq52"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M2"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq52.gif"/></alternatives></inline-formula>-<inline-formula id="IEq53"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M4"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq53.gif"/></alternatives></inline-formula> interaction with Y907. Based on our analysis of these structures, we defined two structural (“receptorAtom”) filters to capture the two interactions. To capture the hydrogen bond, we required that a docked-compound nitrogen or oxygen atom (SMARTS: <italic>[#7,#8]</italic>) come within 5.5 Å of the G863 alpha carbon (<italic>resid</italic>: 863; <italic>atomname</italic>: CA). To capture the <inline-formula id="IEq55"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M6"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq55.gif"/></alternatives></inline-formula>-<inline-formula id="IEq56"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M8"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq56.gif"/></alternatives></inline-formula> interaction, we required that a docked-compound carbon-carbon aromatic bond (SMARTS: <italic>cc</italic>) come within 5.5 Å of the most distal Y907 carbon atom (<italic>resid</italic>: 907; <italic>atomname</italic>: CZ).</p>
        <p id="Par26">To construct filters suitable for the <italic>Hs</italic>PARP1 VS, we examined multiple co-crystallized ligands deposited in the RCSB Protein Data Bank. Many of these positioned peptide-backbone-like substructures (e.g., imidazole- and furan-carboxylic-acid moieties) near where endogenous peptides bind [<xref ref-type="bibr" rid="CR30">30</xref>]. We therefore defined one “coordinate” filter to identify docked poses that positioned <italic>[N,O]CCO</italic> substructures within 4.0 Å of this position. We used a SMARTS string with only sp<sup>3</sup>-hybridized atoms (single bonds) to ensure compatibility with LigGrep’s NONE mode.</p>
        <p id="Par27">To construct filters suitable for the <italic>Hs</italic>Pin1p VS, we again considered known ligands. Many hexokinase ligands are glucose analogues, so we defined a single “coordinate” filter to identify docked poses that positioned a tetrahydro-2<italic>H</italic>-pyran moiety (<italic>C1OCCCC1</italic>) within 1.0 Å of the 3D position where glucose typically binds.</p>
      </sec>
      <sec id="Sec13">
        <title>Measuring virtual screen performance</title>
        <p id="Par28">To evaluate the performance of our VS in terms of both the docked poses and the associated docking scores, we first selected a single candidate pose for each unique input molecule in our library. Given that Gypsum-DL generated up to two molecular variants for each molecule and that Vina predicted up to 9 poses for each variant, each unique molecule was associated with at most 18 poses. In practice this number was smaller on average because in some cases Gypsum-DL generated only one variant, and LigGrep (when applied) filtered out those poses that failed to meet our user-specified criteria. To assess the VS before applying LigGrep, we considered only each ligand’s single, top-scoring pose, without regard for pose geometry. To assess the VS after applying LigGrep, we considered the top-scoring pose from among the poses with geometries that matched our user-defined LigGrep filters.</p>
        <p id="Par29"><bold>Pose accuracy</bold>. To assess how well Vina predicts the poses of known <italic>Hs</italic>PARP1 ligands, we used UCSF Chimera [<xref ref-type="bibr" rid="CR31">31</xref>] to align the 46 <italic>apo</italic><italic>Hs</italic>PARP1 crystal structures listed in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 to the <italic>Hs</italic>PARP1 structure used for docking. We then used the <italic>obrms</italic> program, included in the Open Babel package [<xref ref-type="bibr" rid="CR8">8</xref>], to calculate the root-mean-square deviation (RMSD) between the top-scoring docked pose of each known ligand and the corresponding crystallographic pose (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). We used this same protocol to assess how well Vina predicts the poses of known <italic>Hs</italic>Pin1p and <italic>Sc</italic>Hxk2p ligands (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S2 and S3), though in the case of <italic>Sc</italic>Hxk2p only one crystallographic ligand was available.</p>
        <p id="Par30"><bold>Scoring (ranking) accuracy</bold>. We used several methods to assess how well the three VS ranked known ligands above decoy molecules, both before and after applying LigGrep. First, we ordered the compounds of the three VS by their docking scores and calculated the percentile ranks of the known ligands (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S1–S3). Second, we counted the number of positive-control compounds that ranked in the top 10, 20, and 40 compounds for each VS (Table <xref rid="Tab3" ref-type="table">3</xref>). Third, we calculated enrichment factors. Given a VS of <italic>T</italic> total small molecules including <inline-formula id="IEq74"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{T}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq74.gif"/></alternatives></inline-formula> positive-control compounds, the enrichment factor, <inline-formula id="IEq75"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$EF_{n}$$\end{document}</tex-math><mml:math id="M12"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq75.gif"/></alternatives></inline-formula>, of the <italic>n</italic> top-ranked compounds is the number of positive-control ligands present, <inline-formula id="IEq76"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{n}$$\end{document}</tex-math><mml:math id="M14"><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq76.gif"/></alternatives></inline-formula>, divided by the number of positive controls that would be expected if the compounds were randomly ordered, i.e., <inline-formula id="IEq77"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$EF_{n} = P_{n} / (nP_{T} / T)$$\end{document}</tex-math><mml:math id="M16"><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>F</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:msub><mml:mi>P</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq77.gif"/></alternatives></inline-formula>. Finally, though LigGrep is best used to enrich the set of top-ranked compounds, we also assessed the impact of LigGrep filters on the entire set of ranked compounds using receiver operating characteristic (ROC) metrics (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1).</p>
      </sec>
    </sec>
  </sec>
  <sec id="Sec14">
    <title>Results and discussion</title>
    <sec id="Sec15">
      <title>Benchmark virtual screen: <italic>Hs</italic>PARP1</title>
      <p id="Par31">To demonstrate utility, we first used LigGrep to enrich a VS targeting the <italic>Hs</italic>PARP1 catalytic pocket. <italic>Hs</italic>PARP1 is a highly conserved, multifunctional enzyme that plays important roles in the DNA-damage response. It post-transcriptionally attaches a negatively charged polymer termed poly(ADP-ribose) (PAR) to various protein targets (including itself). These PAR chains recruit proteins that contribute to DNA repair, to the stabilization of DNA replication forks, and to the modification of chromatin structure [<xref ref-type="bibr" rid="CR32">32</xref>]. <italic>Hs</italic>PARP1 is over-expressed in various carcinomas, making it a potential therapeutic target. Additionally, multiple preclinical research studies and clinical trials demonstrate that <italic>Hs</italic>PARP1 inhibition can repress tumor growth and metastasis [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
      <p id="Par32">Although a few <italic>Hs</italic>PARP1 inhibitors have been approved for clinical use (e.g., olaparib, niraparib, and rucaparib) [<xref ref-type="bibr" rid="CR34">34</xref>], clinical trials have revealed a number of therapeutic limitations. These limitations include (1) toxicity due to promiscuous binding, given that most <italic>Hs</italic>PARP1 inhibitors resemble NAD+ [<xref ref-type="bibr" rid="CR35">35</xref>]; (2) activation of viral replication, especially the replication human T-cell lymphotropic virus (HTLV) or Kaposi’s sarcoma-associated herpes virus (KSHV) [<xref ref-type="bibr" rid="CR35">35</xref>]; and (3) acquired resistance that limits long-term use [<xref ref-type="bibr" rid="CR36">36</xref>]. There is thus an urgent need for novel ligands that can be further developed into clinically useful <italic>Hs</italic>PARP1 inhibitors.</p>
      <sec id="Sec16">
        <title>Unfiltered <italic>Hs</italic>PARP1 virtual screen</title>
        <p id="Par33">We first performed a standard VS on <italic>Hs</italic>PARP1 to establish baseline performance. The screen involved 46 co-crystallized (known) <italic>Hs</italic>PARP1 catalytic inhibitors, as well as 1515 additional molecules that served as decoys (presumed inactives). We evaluated our Vina-based docking protocol both in terms of pose-prediction accuracy and the ability to distinguish between known inhibitors and decoy molecules. To evaluate the accuracy of the predicted poses, we calculated heavy-atom RMSDs between the top-scoring docked and crystallographic poses of the 46 known inhibitors included in our small-molecule library. The average RMSD value was 2.82 Å (± 2.04 Å stdev), ranging from 0.48 Å (4OPX:A) to 12.14 Å (4HHY:A). Thirty-one of the known <italic>Hs</italic>PARP1 inhibitors had top-scoring docked poses within 3 Å of the crystallographic pose (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). These RMSD calculations indicate that Vina is reasonably adept at posing the known ligands correctly.</p>
        <p id="Par34">To evaluate how well the Vina-based docking protocol can distinguish between known inhibitors and decoy molecules, we ranked the compounds of our small-molecule library by the docking scores of their top-scoring poses. We found that 45 of 46 known catalytic inhibitors ranked in the top 40%, and 28 ranked in the top 10%. The single highest-scoring compound was in fact a known <italic>Hs</italic>PARP1 catalytic inhibitor (“compound 33” from the 4HHY structure [<xref ref-type="bibr" rid="CR37">37</xref>]); five known ligands were in the top 10 compounds, seven in the top 20, and 13 in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).<table-wrap id="Tab3"><label>Table 3</label><caption><p>The number of known ligands caught in the top 10, 20, and 40 highest-scoring compounds of each VS when docking with Vina only vs. Vina + LigGrep</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Screen type</th><th align="left">Top 10</th><th align="left">Top 20</th><th align="left">Top 40</th></tr></thead><tbody><tr><td align="left"><italic>Hs</italic>PARP1</td><td align="left">Vina only</td><td align="left">5/46</td><td align="left">7/46</td><td align="left">13/46</td></tr><tr><td align="left"><italic>Hs</italic>PARP1</td><td align="left">Vina + LigGrep</td><td align="left">7/46</td><td align="left">11/46</td><td align="left">19/46</td></tr><tr><td align="left"><italic>Hs</italic>Pin1p</td><td align="left">Vina only</td><td align="left">2/27</td><td align="left">3/27</td><td align="left">5/27</td></tr><tr><td align="left"><italic>Hs</italic>Pin1p</td><td align="left">Vina + LigGrep</td><td align="left">3/27</td><td align="left">4/27</td><td align="left">8/27</td></tr><tr><td align="left"><italic>Sc</italic>Hxk2p</td><td align="left">Vina only</td><td align="left">2/41</td><td align="left">4/41</td><td align="left">6/41</td></tr><tr><td align="left"><italic>Sc</italic>Hxk2p</td><td align="left">Vina + LigGrep</td><td align="left">4/41</td><td align="left">6/41</td><td align="left">7/41</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec17">
        <title>LigGrep-filtered <italic>Hs</italic>PARP1 virtual screen</title>
        <p id="Par35">To show how LigGrep can further improve the hit rate of this high-performing VS, we filtered the docked poses of all library compounds to identify those predicted to participate in a hydrogen bond with the <italic>Hs</italic>PARP1 G863 residue and a <inline-formula id="IEq107"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M18"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq107.gif"/></alternatives></inline-formula>-<inline-formula id="IEq108"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M20"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq108.gif"/></alternatives></inline-formula> interaction with Y907 (Table <xref rid="Tab3" ref-type="table">3</xref>, see “<xref rid="Sec2" ref-type="sec">Implementation</xref>” for details). LigGrep filtered out 435 of the 1561 unique compounds (ligands + decoys) in the virtual library. We ranked (by docking score) the remaining 1126 unique compounds with poses that matched our filter criteria.</p>
        <p id="Par36">Importantly, LigGrep allowed us to effectively consider all the poses associated with each docked compound, not just the top-scoring pose. Given our Gypsum-DL/Vina protocol (see “<xref rid="Sec2" ref-type="sec">Implementation</xref>”) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], each unique compound in our library was associated with up to 18 predicted poses. Manually inspecting so many poses is impossible. Our approach in the past has been to consider only the top-scoring pose associated with each Vina run, and then to visually inspect only the poses of the top-ranked docked compounds. LigGrep now allows us to consider all docked poses associated with each candidate ligand, not just the top-scoring pose.</p>
        <p id="Par37">After we used LigGrep to filter out less-likely poses, seven known ligands ranked in the top 10 highest-scoring compounds, 11 in the top 20, and 19 in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). In fact the top four ranked compounds were all known <italic>Hs</italic>PARP1 inhibitors. LigGrep thus improved the hit rate among the top-scoring compounds over that obtained using the unfiltered VS. Similar improvements can be seen in enrichment factors (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) and areas under the pROC curve (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1 and Table S4).<fig id="Fig2"><label>Fig. 2</label><caption><p>Enrichment factors associated with our <italic>Hs</italic>PARP1,<italic>Hs</italic>Pin1p, and <italic>Sc</italic>Hxk2p VS, before (blue) and after (orange) applying LigGrep filters. To calculate the enrichment factors of the LigGrep-filtered VS, any compound that did not pass the filter(s), whether a positive control or decoy, was moved to the bottom of the ranked list</p></caption><graphic xlink:href="13321_2020_471_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec18">
      <title>Benchmark virtual screen: <italic>Hs</italic>Pin1p</title>
      <p id="Par38">To further demonstrate utility, we also applied LigGrep to a VS targeting <italic>Hs</italic>Pin1p. <italic>Hs</italic>Pin1p binds to proteins with phosphorylated serine/threonine-proline (pSer/Thr-Pro) motifs and accelerates the cis–trans isomerization of the proline residue. Peptidyl-prolyl isomerization can be seen as a kind of post-translational modification that impacts how many proteins fold, localize, activate, and interact [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. <italic>Hs</italic>Pin1p is upregulated in many cancers, likely because many of its targets contribute to cancer pathogenesis. Reduced <italic>Hs</italic>Pin1p activity protects against cancer progression [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref>], so much effort has been invested in developing <italic>Hs</italic>Pin1p inhibitors [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
      <sec id="Sec19">
        <title>Unfiltered <italic>Hs</italic>Pin1p virtual screen</title>
        <p id="Par39">As with <italic>Hs</italic>PARP1, we first performed a standard <italic>Hs</italic>Pin1p VS to establish baseline performance. The screen involved 27 co-crystallized (known) <italic>Hs</italic>Pin1p inhibitors, as well as 1515 additional molecules that served as decoys (presumed inactives). The average heavy-atom RMSD between the top-scoring docked and crystallographic poses of the 27 known inhibitors was 3.43 Å (± 2.33 Å stdev), ranging from 0.26 Å (2XP6:A) to 8.63 Å (3TDB:A). Fourteen of the known <italic>Hs</italic>Pin1p inhibitors had top-scoring docked poses within 3 Å of the crystallographic pose (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p>
        <p id="Par40">We again ranked the compounds of our small-molecule library by the docking scores of their top-scoring poses. We found that 23 of 27 known inhibitors ranked in the top 40%, and 12 ranked in the top 10%. Two known ligands were in the top 10 compounds, three in the top 20, and five in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p>
      </sec>
      <sec id="Sec20">
        <title>LigGrep-filtered <italic>Hs</italic>Pin1p virtual screen</title>
        <p id="Par41">To show how LigGrep can further improve the hit rate of the <italic>Hs</italic>Pin1p VS, we filtered the docked poses of all library compounds to identify those that positioned peptide-backbone-like substructures near where endogenous peptides bind (Table <xref rid="Tab3" ref-type="table">3</xref>, see “<xref rid="Sec2" ref-type="sec">Implementation</xref>” for details) [<xref ref-type="bibr" rid="CR30">30</xref>]. Given that this substructure is very specific, LigGrep filtered out 1029 of the 1542 unique ligands and decoys. We ranked (by docking score) the remaining 513 unique compounds with poses that matched our filter criteria, including 25 of the known ligands.</p>
        <p id="Par42">After LigGrep filtering, three known ligands ranked in the top 10 highest-scoring compounds, four in the top 20, and eight in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). LigGrep thus improved the hit rate among the top-scoring compounds. In fact the top-ranked compound after LigGrep filtering was the known <italic>Hs</italic>Pin1p inhibitor 3-(6-fluoro-1H-benzimidazol-2-yl)-N-(naphthalen-2-ylcarbonyl)-D-alanine, with a measured K<sub>i</sub> of 80 nM [<xref ref-type="bibr" rid="CR45">45</xref>]. The enrichment factors (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) and areas under the pROC curve similarly improved (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1 and Table S4).</p>
      </sec>
    </sec>
    <sec id="Sec21">
      <title>Benchmark virtual screen: <italic>Sc</italic>Hxk2p</title>
      <p id="Par43">As a final demonstration, we applied LigGrep to a VS targeting <italic>Sc</italic>Hxk2p. Hexokinases perform the first step in glucose metabolism, transferring an ATP <inline-formula id="IEq135"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma$$\end{document}</tex-math><mml:math id="M22"><mml:mi>γ</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq135.gif"/></alternatives></inline-formula> phosphate to a glucose C6 carbon atom to produce glucose-6-phosphate (Glc-6P) [<xref ref-type="bibr" rid="CR46">46</xref>]. This activated Glc-6P is critical for downstream catabolic processes such as anaerobic fermentation [<xref ref-type="bibr" rid="CR47">47</xref>] and aerobic oxidative phosphorylation (OXPHOS) [<xref ref-type="bibr" rid="CR47">47</xref>], as well as anabolic pathways such as the pentose–phosphate shunt [<xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR50">50</xref>].</p>
      <p id="Par44">Glucose metabolism is often dysregulated in cancer. Cancer cells tend to use glycolysis and lactic acid fermentation to generate ATP from glucose, even when adequate oxygen is available for the more efficient OXPHOS [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR55">55</xref>]. To maintain ATP levels, cancer cells must increase glycolytic flux [<xref ref-type="bibr" rid="CR50">50</xref>], often by upregulating hexokinase II (<italic>Hs</italic>HK2p) [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Several groups have developed small-molecule <italic>Hs</italic>HK2p ligands that bind to the catalytic pocket [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR63">63</xref>], but acquired resistance [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR71">71</xref>] and unacceptable toxicities [<xref ref-type="bibr" rid="CR72">72</xref>] require the development of additional hexokinase inhibitors.</p>
      <sec id="Sec22">
        <title>Unfiltered <italic>Sc</italic>Hxk2p virtual screen</title>
        <p id="Par45">We first performed a standard <italic>Sc</italic>Hxk2p VS to establish baseline performance. We designed this VS to determine whether LigGrep can enhance performance even in challenging circumstances. First, rather than limit our set of positive controls (“known ligands”) to <italic>Sc</italic>Hxk2p ligands, we selected 41 glucose analogues known to bind hexokinases and glucokinases from any of several species. It is therefore likely that some of our “positive controls” are not true <italic>Sc</italic>Hxk2p ligands, effectively injecting noise into our VS signal. To further exacerbate this challenge, we selected molecules that are chemically similar to the positive controls to serve as presumed inactive decoys (i.e., 1652 glucose analogues present in the ChemDiv and eMolecules databases).</p>
        <p id="Par46">Second, we of necessity had to limit our pre-VS assessment of pose accuracy. Only one of the selected positive-control compounds (ortho-toluoylglucosamine [<xref ref-type="bibr" rid="CR73">73</xref>]) has been co-crystallized with <italic>Sc</italic>Hxk2p. The heavy-atom RMSD between the top-scoring and crystallographic poses of this compound was 1.90 Å, suggesting that Vina is well suited to <italic>Sc</italic>Hxk2p docking, but the available structures permit only this one data point as validation.</p>
        <p id="Par47">We again ranked the compounds of our small-molecule library by the docking scores of their top-scoring poses. We found that 26 of 41 positive-control compounds ranked in the top 40%, and 12 ranked in the top 10%. Two were in the top 10 compounds, four in the top 20, and six in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).</p>
      </sec>
      <sec id="Sec23">
        <title>LigGrep-filtered <italic>Sc</italic>Hxk2p virtual screen</title>
        <p id="Par48">To show how LigGrep can improve the hit rate of the <italic>Sc</italic>Hxk2p VS, we filtered the docked poses of all library compounds to identify those that positioned a glucose-like (tetrahydro-2<italic>H</italic>-pyran) moiety near the location where glucose, the endogenous substrate, binds (Table <xref rid="Tab3" ref-type="table">3</xref>, see “<xref rid="Sec2" ref-type="sec">Implementation</xref>” for details) [<xref ref-type="bibr" rid="CR74">74</xref>]. LigGrep filtered out 428 of the 1693 unique compounds in the virtual library. We ranked (by docking score) the remaining 1265 unique compounds with poses that matched our filter criteria, including 40 of the positive-control compounds. After LigGrep filtering, the number of positive controls in the top 10 highest-scoring compounds doubled to four. Six positive controls ranked in the top 20, and seven in the top 40 (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). The enrichment factors (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) and areas under the pROC curve also improved (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1 and Table S4).</p>
      </sec>
    </sec>
    <sec id="Sec24">
      <title>LigGrep advantages and disadvantages</title>
      <p id="Par49">To illustrate the advantages and disadvantages of the LigGrep approach, we now consider in detail several of the docked poses from our <italic>Hs</italic>PARP1 VS.</p>
      <sec id="Sec25">
        <title>Examples that illustrate LigGrep advantages</title>
        <p id="Par50">LigGrep can improve hit rates by (1) eliminating compounds that are less likely to bind the target protein, and (2) allowing researchers to consider all poses (rather than only the top-scoring pose) when searching for potential ligands. The low-nanomolar <italic>Hs</italic>PARP1 inhibitor olaparib [<xref ref-type="bibr" rid="CR28">28</xref>] illustrates the first advantage (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a). The docked and crystallographic poses of olaparib were similar (RMSD: 2.7 Å; Fig. <xref rid="Fig3" ref-type="fig">3</xref>a in green and pink, respectively) [<xref ref-type="bibr" rid="CR75">75</xref>]. Prior to LigGrep filtering, olaparib ranked third in our VS (−12.1 kcal/mol), behind a presumed decoy in second place. But none of the poses associated with the second-place compound passed the filters, so olaparib moved from third to second.<fig id="Fig3"><label>Fig. 3</label><caption><p>Example poses taken from a benchmark <italic>Hs</italic>PARP1 VS. Docked ligand poses are shown in green, and the <italic>Hs</italic>PARP1 receptor (PDB: 6BHV) is shown in blue. The atoms used to define the hydrogen-bond and <inline-formula id="IEq162"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M24"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq162.gif"/></alternatives></inline-formula>-<inline-formula id="IEq163"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pi$$\end{document}</tex-math><mml:math id="M26"><mml:mi>π</mml:mi></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq163.gif"/></alternatives></inline-formula> LigGrep filters (metallic spheres) are labeled with an asterisk and dagger, respectively. <bold>a</bold> Olaparib, with a generally correct docked pose that passed all LigGrep filters. The crystallographic pose is shown in pink. <bold>b</bold> Tricinolone acetophenonide (NSC37641), a high-scoring decoy molecule, had a top-scoring docked pose did not pass LigGrep filters (in pink), but a lower-scoring pose that did (in green). <bold>c</bold> Compound 33, with an incorrect docked pose that nevertheless passed LigGrep filters. The crystallographic pose is shown in pink. <bold>d</bold> Amitriptyline, a true ligand that could not have passed LigGrep filters, regardless of pose accuracy. The crystallographic pose is shown in pink</p></caption><graphic xlink:href="13321_2020_471_Fig3_HTML" id="MO3"/></fig></p>
        <p id="Par51">Tricinolone acetophenonide (NSC37641), a high-scoring decoy molecule, illustrates the second advantage of the LigGrep approach (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b). The top-scoring pose of this compound (in pink) has a Vina docking score of −10.4 kcal/mol, but it does not position an oxygen or nitrogen atom close enough to the <italic>Hs</italic>PARP1 G863 residue, as required by one of our LigGrep filters. Had we manually inspected only the top-scoring pose associated with each ligand, we may therefore have discarded this compound, despite its impressive docking score (top <inline-formula id="IEq158"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sim$$\end{document}</tex-math><mml:math id="M28"><mml:mo>∼</mml:mo></mml:math><inline-graphic xlink:href="13321_2020_471_Article_IEq158.gif"/></alternatives></inline-formula>3% of all compounds). But LigGrep allowed us to identify a second, slightly lower-scoring pose (−10.2 kcal/mol) that did in fact position a compound hydroxyl group near the G863 residue. Of course, tricinolone acetophenonide is not known to inhibit <italic>Hs</italic>PARP1, and it was in fact included in the screen as a decoy (presumed inactive) compound. But this example nevertheless illustrates how LigGrep allows researchers to identify reasonable albeit lower-scoring docked poses, even when the top-scoring pose is implausible.</p>
      </sec>
      <sec id="Sec26">
        <title>Examples that illustrate LigGrep disadvantages</title>
        <p id="Par53">By way of disadvantages, we note that (1) some incorrect poses nevertheless pass LigGrep filters, and (2) some true ligands may not contain the substructures required to pass, regardless of pose accuracy. “Compound 33,” a low-nanomolar benzo[<italic>de</italic>][1,7]naphthyridin-7(8<italic>H</italic>)-one inhibitor [<xref ref-type="bibr" rid="CR37">37</xref>], illustrates the first disadvantage. Though it was the top-scoring compound in our VS (−13.4 kcal/mol) and passed our LigGrep filters, its pose is notably incorrect (12.1 Å RMSD from the crystallographic pose). The inhibitor coincidentally has similar substructures at both its ends: phthalazin-1(2<italic>H</italic>)-one and 3,4-dihydroisoquinolin-1(2<italic>H</italic>)-one, respectively. In the docked pose (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c, green), the compound was flipped in the binding pocket relative to the crystallographic pose (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c, pink), such that the phthalazin-1(2<italic>H</italic>)-one substructure satisfied the filters rather than the (correct) 3,4-dihydroisoquinolin-1(2<italic>H</italic>)-one substructure.</p>
        <p id="Par54">Amitriptyline provides an example of the second disadvantage of the LigGrep approach. This low-micromolar <italic>Hs</italic>PARP1 ligand ranked 229th out of 1561 compounds (−9.2 kcal/mol, 15th percentile) in our pre-LigGrep VS, and its docked and crystallographic poses were fairly similar (RMSD 3.8 Å, Fig. <xref rid="Fig3" ref-type="fig">3</xref>d, green and pink, respectively) [<xref ref-type="bibr" rid="CR76">76</xref>]. But amitriptyline lacks a nitrogen/oxygen atom adjacent to an aromatic ring and so could not ever pass our LigGrep filters, regardless of its pose.</p>
      </sec>
    </sec>
    <sec id="Sec27">
      <title>Comparison with existing programs</title>
      <p id="Par55">Several powerful commercial docking programs also allow users to filter docked poses or to otherwise apply constraints during the docking process. LigGrep’s main advantage is that it can be applied to VS performed with free, open-source docking programs that often lack built-in pose filters. In contrast, commercial programs are often expensive and have restrictive licenses that impose substantial commercialization and intellectual-property restrictions. Furthermore, in some cases license eligibility is regularly re-evaluated, making long-term access uncertain. We here compare two commercial programs to LigGrep and describe how LigGrep can complement their native functionality.</p>
      <sec id="Sec50">
        <title>Schrödinger Glide</title>
        <p id="Par56">Schrödinger’s Glide [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>] is a state-of-the-art commercial docking program that allows the user to apply constraints both during the docking process (such that they impact poses and scores) or after docking (as post-VS filters similar to LigGrep). Glide can account for (1) positional filters, which require a given docked-compound atom to occupy a user-defined spherical region; (2) excluded volumes, which require the compound to avoid defined regions of space; (3) nuclear Overhauser effect (NOE) constraints, which require a given protein/ligand atom-atom distance to fall within a user-provided range; and (4) hydrogen-bond/metal/metal-coordination constraints, which require the candidate ligand to form key interactions with receptor functional groups [<xref ref-type="bibr" rid="CR79">79</xref>]. The positional and excluded-volume filters are notably similar to those that LigGrep implements.</p>
        <p id="Par57">We anticipate that most Glide users will prefer to use Glide’s built-in constraints, but it is certainly possible to apply LigGrep filters to Glide-docked poses as well. Schrödinger’s Maestro Suite can export protein receptor and small-molecule models as PDB and SDF files, respectively [<xref ref-type="bibr" rid="CR78">78</xref>], formats that LigGrep can in turn accept as input.</p>
      </sec>
      <sec id="Sec49">
        <title>OpenEye FRED</title>
        <p id="Par58">OpenEye’s FRED is another popular commercial docking program that includes both protein and custom filters [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. A FRED protein filter is satisfied when a docked compound is predicted to participate in a user-specified interaction (hydrogen bond, metal-chelator, contact, etc.) with a given protein atom. A custom filter is satisfied when a SMARTS-specified small-molecule substructure occupies a user-specified sphere. This last filter type in particular is very reminiscent of the LigGrep approach. As with Glide, FRED can also output docked poses in the SDF format, so LigGrep filters can be applied to FRED-docked poses as well.</p>
      </sec>
    </sec>
  </sec>
  <sec id="Sec28">
    <title>Conclusion</title>
    <p id="Par59">LigGrep allows researchers performing VS to improve hit rates by leveraging prior knowledge about key receptor/ligand interactions known to correlate with activity. Our results demonstrate that LigGrep can effectively filter out decoy molecules while retaining known ligands. In three separate test cases, LigGrep filtering improved hit rates over those obtained using AutoDock Vina alone. LigGrep will be a useful tool for the CADD community. We release it under the terms of the Apache License, Version 2.0. A copy is freely available at <ext-link ext-link-type="uri" xlink:href="http://durrantlab.com/liggrep/">http://durrantlab.com/liggrep/</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary information</title>
    <sec id="Sec51">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13321_2020_471_MOESM1_ESM.pdf">
            <caption>
              <p><bold>Additional file 1: Table S1.</bold> Poly(ADP-ribose) polymerase 1 (PARP1) virtual screen, before and after applying two LigGrep filters (detailed results). <bold>Table S2.</bold>
<italic>H. sapiens</italic> peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (<italic>Hs</italic>Pin1p) virtual screen, before and after applying a LigGrep filter (detailed results). <bold>Table S3.</bold>
<italic>S. cerevisiae</italic> hexokinase-2 (<italic>Sc</italic>Hxk2p) virtual screen, before and after applying a LigGrep filter (detailed results). <bold>Table S4.</bold> AUROC and pAUROC values before and after LigGrep filtering. <bold>Figure S1.</bold> pROC curves describing our PARP1, <italic>Hs</italic>Pin1p, and <italic>Sc</italic>Hxk2p VS, before (blue) and after (orange) applying LigGrep filters.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary information</title>
    <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13321-020-00471-2.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>We thank Bhav Jain for helpful early-stage discussions and prototyping. We also acknowledge the University of Pittsburgh’s Center for Research Computing for providing computer resources.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors' contributions</title>
    <p>EJH and JDD wrote the final codebase, drafted the manuscript, and prepared the figures. CTL contributed to an early prototype of the codebase and critically reviewed/edited the manuscript. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health [R01GM132353 to J.D.D.]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>Project name: LigGrep 1.0.0. Project home page: <ext-link ext-link-type="uri" xlink:href="http://durrantlab.com/liggrep">http://durrantlab.com/liggrep</ext-link>. Operating systems: macOS, Linux, Windows. Programming language: Python 3. Other requirements: RDKit, NumPy, SciPy, Open Babel (optional). License: Apache License, Version 2.0. Restrictions to use by non-academics: None</p>
  </notes>
  <notes id="FPar2" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par64">The authors declare that they have no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sliwoski</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kothiwale</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Meiler</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lowe</surname>
            <given-names>EW</given-names>
          </name>
        </person-group>
        <article-title>Computational methods in drug discovery</article-title>
        <source>Pharmacol Rev</source>
        <year>2014</year>
        <volume>66</volume>
        <fpage>334</fpage>
        <lpage>95</lpage>
        <?supplied-pmid 24381236?>
        <pub-id pub-id-type="pmid">24381236</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kontoyianni</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Docking and virtual screening in drug discovery</article-title>
        <source>Methods Mol Biol</source>
        <year>2017</year>
        <volume>1647</volume>
        <fpage>255</fpage>
        <lpage>266</lpage>
        <?supplied-pmid 28809009?>
        <pub-id pub-id-type="pmid">28809009</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lape</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Elam</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Paula</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Comparison of current docking tools for the simulation of inhibitor binding by the transmembrane domain of the sarco/endoplasmic reticulum calcium ATPase</article-title>
        <source>Biophys Chem</source>
        <year>2010</year>
        <volume>150</volume>
        <fpage>88</fpage>
        <lpage>97</lpage>
        <?supplied-pmid 20167416?>
        <pub-id pub-id-type="pmid">20167416</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ropp</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Spiegel</surname>
            <given-names>JO</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Morales</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Milliken</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Ringe</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
        </person-group>
        <article-title>Gypsum-DL: an open-source program for preparing small-molecule libraries for structure-based virtual screening</article-title>
        <source>J Cheminform</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>34</fpage>
        <?supplied-pmid 31127411?>
        <pub-id pub-id-type="pmid">31127411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Varghese</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Sollis</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Blick</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Sahasrabudhe</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>McKimm-Breschkin</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Colman</surname>
            <given-names>PM</given-names>
          </name>
        </person-group>
        <article-title>Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase</article-title>
        <source>Structure</source>
        <year>1998</year>
        <volume>6</volume>
        <fpage>735</fpage>
        <lpage>46</lpage>
        <?supplied-pmid 9655825?>
        <pub-id pub-id-type="pmid">9655825</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trott</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>
        <source>J Comput Chem</source>
        <year>2009</year>
        <volume>31</volume>
        <fpage>455</fpage>
        <lpage>461</lpage>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ropp</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Friedman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
        </person-group>
        <article-title>Scoria: a Python module for manipulating 3D molecular data</article-title>
        <source>J Cheminfor</source>
        <year>2017</year>
        <volume>9</volume>
        <fpage>52</fpage>
        <lpage>58</lpage>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O’Boyle</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Banck</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Morley</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vandermeersch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hutchison</surname>
            <given-names>GR</given-names>
          </name>
        </person-group>
        <article-title>Open babel: an open chemical toolbox</article-title>
        <source>J Cheminf</source>
        <year>2011</year>
        <volume>3</volume>
        <fpage>33</fpage>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <mixed-citation publication-type="other">Landrum G, RDKit: open-source cheminformatics, Web Page</mixed-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Oliphant</surname>
            <given-names>TE</given-names>
          </name>
        </person-group>
        <source>Guide to NumPy</source>
        <year>2006</year>
        <publisher-loc>Provo</publisher-loc>
        <publisher-name>Brigham Young University</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <mixed-citation publication-type="other">Jones E, Oliphant T, Peterson P et al (2001) SciPy: Open Source Scientific Tools for Python, Computer Program</mixed-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Langelier</surname>
            <given-names>M-F</given-names>
          </name>
          <name>
            <surname>Zandarashvili</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Aguiar</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Pascal</surname>
            <given-names>JM</given-names>
          </name>
        </person-group>
        <article-title>NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains</article-title>
        <source>Nat Commun</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>844</fpage>
        <?supplied-pmid 29487285?>
        <pub-id pub-id-type="pmid">29487285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>XJ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Bowman</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Noel</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Ellington</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Etzkorn</surname>
            <given-names>FA</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Structural and kinetic analysis of prolyl-isomerization/phosphorylation cross-talk in the CTD code</article-title>
        <source>ACS Chem Biol</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>1462</fpage>
        <lpage>70</lpage>
        <?supplied-pmid 22670809?>
        <pub-id pub-id-type="pmid">22670809</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kuser</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>Krauchenco</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Antunes</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Polikarpov</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>The high resolution crystal structure of yeast hexokinase PII with the correct primary sequence provides new insights into its mechanism of action</article-title>
        <source>J Biol Chem</source>
        <year>2000</year>
        <volume>275</volume>
        <fpage>20814</fpage>
        <lpage>20821</lpage>
        <?supplied-pmid 10749890?>
        <pub-id pub-id-type="pmid">10749890</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berman</surname>
            <given-names>HM</given-names>
          </name>
        </person-group>
        <article-title>The protein data bank</article-title>
        <source>Biol Crystallography Acta Crystallographica Sect D</source>
        <year>2000</year>
        <pub-id pub-id-type="doi">10.1107/S0907444902003451</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berman</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Westbrook</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bhat</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Weissig</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shindyalov</surname>
            <given-names>IN</given-names>
          </name>
          <name>
            <surname>Bourne</surname>
            <given-names>PE</given-names>
          </name>
        </person-group>
        <article-title>The protein data bank</article-title>
        <source>Nucleic Acids Res</source>
        <year>2000</year>
        <volume>28</volume>
        <fpage>235</fpage>
        <lpage>242</lpage>
        <?supplied-pmid 102472?>
        <pub-id pub-id-type="pmid">10592235</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gazgalis</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zaka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abbasi</surname>
            <given-names>BH</given-names>
          </name>
          <name>
            <surname>Logothetis</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Mezei</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Protein binding pocket optimization for virtual high-throughput screening (vHTS) drug discovery</article-title>
        <source>ACS Omega</source>
        <year>2020</year>
        <volume>5</volume>
        <fpage>14297</fpage>
        <lpage>14307</lpage>
        <?supplied-pmid 32596567?>
        <pub-id pub-id-type="pmid">32596567</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Baumgartner</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Camacho</surname>
            <given-names>CJ</given-names>
          </name>
        </person-group>
        <article-title>Protein binding pocket optimization for virtual high-throughput screening (vHTS) drug discovery</article-title>
        <source>J Chem Inform Modeling</source>
        <year>2016</year>
        <volume>56</volume>
        <fpage>1004</fpage>
        <lpage>12</lpage>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ren</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Clementi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Krishnan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>WW</given-names>
          </name>
        </person-group>
        <article-title>Opal web services for biomedical applications</article-title>
        <source>Nucleic Acids Res</source>
        <year>2010</year>
        <volume>38</volume>
        <fpage>W724</fpage>
        <lpage>31</lpage>
        <?supplied-pmid 20529877?>
        <pub-id pub-id-type="pmid">20529877</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dolinsky</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>McCammon</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>NA</given-names>
          </name>
        </person-group>
        <article-title>PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations</article-title>
        <source>Nucleic Acids Res</source>
        <year>2004</year>
        <volume>32</volume>
        <fpage>W665</fpage>
        <lpage>W667</lpage>
        <?supplied-pmid 15215472?>
        <pub-id pub-id-type="pmid">15215472</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dolinsky</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Czodrowski</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Klebe</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>NA</given-names>
          </name>
        </person-group>
        <article-title>PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations</article-title>
        <source>Nucleic Acids Res</source>
        <year>2007</year>
        <volume>35</volume>
        <fpage>W522</fpage>
        <lpage>W525</lpage>
        <?supplied-pmid 17488841?>
        <pub-id pub-id-type="pmid">17488841</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Ruth</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lindstrom</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sanner</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Belew</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Goodsell</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title>
        <source>J Comput Chem</source>
        <year>2009</year>
        <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>
        <?supplied-pmid 19399780?>
        <pub-id pub-id-type="pmid">19399780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <mixed-citation publication-type="other">National Cancer Institute. <ext-link ext-link-type="uri" xlink:href="https://dtp.cancer.gov/organization/dscb/obtaining/available_plates.htm">https://dtp.cancer.gov/organization/dscb/obtaining/available_plates.htm</ext-link>. Accessed 30 Oct 2020</mixed-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Jorissen</surname>
            <given-names>RN</given-names>
          </name>
          <name>
            <surname>Gilson</surname>
            <given-names>MK</given-names>
          </name>
        </person-group>
        <article-title>BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities</article-title>
        <source>Nucleic Acids Res</source>
        <year>2007</year>
        <volume>35</volume>
        <fpage>D198</fpage>
        <lpage>201</lpage>
        <?supplied-pmid 17145705?>
        <pub-id pub-id-type="pmid">17145705</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gilson</surname>
            <given-names>MK</given-names>
          </name>
        </person-group>
        <article-title>The binding database: data management and interface design</article-title>
        <source>Bioinformatics</source>
        <year>2002</year>
        <volume>18</volume>
        <fpage>130</fpage>
        <lpage>139</lpage>
        <?supplied-pmid 11836221?>
        <pub-id pub-id-type="pmid">11836221</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kochnev</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hellemann</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cassidy</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
        </person-group>
        <article-title>Webina: an open-source library and web app that runs AutoDock vina entirely in the web browser</article-title>
        <source>Bioinformatics</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa579</pub-id>
        <?supplied-pmid 32559277?>
        <pub-id pub-id-type="pmid">32559277</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Spiegel</surname>
            <given-names>JO</given-names>
          </name>
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
        </person-group>
        <article-title>AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization</article-title>
        <source>J Cheminform</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>1</fpage>
        <lpage>16</lpage>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thorsell</surname>
            <given-names>A-G</given-names>
          </name>
          <name>
            <surname>Ekblad</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Karlberg</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Löw</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pinto</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Trésaugues</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Moche</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Schuler</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Structural Basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors</article-title>
        <source>J Med Chem</source>
        <year>2017</year>
        <volume>60</volume>
        <fpage>1262</fpage>
        <lpage>1271</lpage>
        <?supplied-pmid 28001384?>
        <pub-id pub-id-type="pmid">28001384</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kinoshita</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nakanishi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Warizaya</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Iwashita</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kido</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hattori</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Fujii</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase</article-title>
        <source>FEBS Lett</source>
        <year>2004</year>
        <volume>556</volume>
        <fpage>43</fpage>
        <lpage>6</lpage>
        <?supplied-pmid 14706823?>
        <pub-id pub-id-type="pmid">14706823</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Daum</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wildemann</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>XZ</given-names>
          </name>
          <name>
            <surname>Verdecia</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Bowman</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Lucke</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>K-P</given-names>
          </name>
          <name>
            <surname>Fischer</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Noel</surname>
            <given-names>JP</given-names>
          </name>
        </person-group>
        <article-title>Structural basis for high-affinity peptide inhibition of human Pin1</article-title>
        <source>ACS Chem Biol</source>
        <year>2007</year>
        <volume>2</volume>
        <fpage>320</fpage>
        <lpage>8</lpage>
        <?supplied-pmid 17518432?>
        <pub-id pub-id-type="pmid">17518432</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pettersen</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>Goddard</surname>
            <given-names>TD</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Couch</surname>
            <given-names>GS</given-names>
          </name>
          <name>
            <surname>Greenblatt</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Ferrin</surname>
            <given-names>TE</given-names>
          </name>
        </person-group>
        <article-title>UCSF chimera—a visualization system for exploratory research and analysis</article-title>
        <source>J Comput Chem</source>
        <year>2004</year>
        <volume>25</volume>
        <fpage>1605</fpage>
        <lpage>1612</lpage>
        <?supplied-pmid 15264254?>
        <pub-id pub-id-type="pmid">15264254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chaudhuri</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Nussenzweig</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</article-title>
        <source>Natu Rev Mol Cell Biol</source>
        <year>2017</year>
        <volume>18</volume>
        <fpage>610</fpage>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Guan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs</article-title>
        <source>Int J Mol Sci</source>
        <year>2017</year>
        <pub-id pub-id-type="doi">10.3390/ijms18102111</pub-id>
        <?supplied-pmid 29295552?>
        <pub-id pub-id-type="pmid">29295552</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Bai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</article-title>
        <source>Cancer Manag Res</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>4371</fpage>
        <lpage>4390</lpage>
        <?supplied-pmid 31191001?>
        <pub-id pub-id-type="pmid">31191001</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malyuchenko</surname>
            <given-names>NV</given-names>
          </name>
          <name>
            <surname>Kotova</surname>
            <given-names>EY</given-names>
          </name>
          <name>
            <surname>Kulaeva</surname>
            <given-names>OI</given-names>
          </name>
          <name>
            <surname>Kirpichnikov</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Studitskiy</surname>
            <given-names>VM</given-names>
          </name>
        </person-group>
        <article-title>PARP1 inhibitors: antitumor drug design</article-title>
        <source>Acta Naturae</source>
        <year>2015</year>
        <volume>7</volume>
        <fpage>27</fpage>
        <lpage>37</lpage>
        <?supplied-pmid 26483957?>
        <pub-id pub-id-type="pmid">26483957</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Montoni</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Robu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pouliot</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>GM</given-names>
          </name>
        </person-group>
        <article-title>Resistance to PARP-inhibitors in cancer therapy</article-title>
        <source>Front Pharmacol</source>
        <year>2013</year>
        <volume>4</volume>
        <fpage>18</fpage>
        <?supplied-pmid 23450678?>
        <pub-id pub-id-type="pmid">23450678</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ye</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C-H</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J-X</given-names>
          </name>
          <name>
            <surname>Huan</surname>
            <given-names>X-J</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>S-S</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Miao</surname>
            <given-names>Z-H</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</article-title>
        <source>J Med Chem</source>
        <year>2013</year>
        <volume>56</volume>
        <fpage>2885</fpage>
        <lpage>903</lpage>
        <?supplied-pmid 23473053?>
        <pub-id pub-id-type="pmid">23473053</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y-R</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>H-Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X-Z</given-names>
          </name>
          <name>
            <surname>Jie</surname>
            <given-names>M-M</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>C-J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y-Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>S-M</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y-B</given-names>
          </name>
        </person-group>
        <article-title>Prolyl isomerase Pin1: a promoter of cancer and a target for therapy</article-title>
        <source>Cell Death Dis</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>883</fpage>
        <?supplied-pmid 30158600?>
        <pub-id pub-id-type="pmid">30158600</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Göthel</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Marahiel</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts</article-title>
        <source>Cell Mol Life Sci</source>
        <year>1999</year>
        <volume>55</volume>
        <fpage>423</fpage>
        <lpage>36</lpage>
        <?supplied-pmid 10228556?>
        <pub-id pub-id-type="pmid">10228556</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Takahashi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Uchida</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>R-W</given-names>
          </name>
          <name>
            <surname>Shimazaki</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Uchida</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer’s disease</article-title>
        <source>Cell Mol Life Sci</source>
        <year>2008</year>
        <volume>65</volume>
        <fpage>359</fpage>
        <lpage>75</lpage>
        <?supplied-pmid 17965833?>
        <pub-id pub-id-type="pmid">17965833</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Finn</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Nicholson</surname>
            <given-names>LK</given-names>
          </name>
        </person-group>
        <article-title>Prolyl cis-trans isomerization as a molecular timer</article-title>
        <source>Nat Chem Biol</source>
        <year>2007</year>
        <volume>3</volume>
        <fpage>619</fpage>
        <lpage>29</lpage>
        <?supplied-pmid 17876319?>
        <pub-id pub-id-type="pmid">17876319</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>D’Artista</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bisso</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Piontini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Doni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Verrecchia</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kress</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Morelli</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Del Sal</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Amati</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Campaner</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc</article-title>
        <source>Oncotarget</source>
        <year>2016</year>
        <volume>7</volume>
        <fpage>21786</fpage>
        <lpage>98</lpage>
        <?supplied-pmid 26943576?>
        <pub-id pub-id-type="pmid">26943576</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wulf</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Garg</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Liou</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Iglehart</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>KP</given-names>
          </name>
        </person-group>
        <article-title>Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis</article-title>
        <source>EMBO J</source>
        <year>2004</year>
        <volume>23</volume>
        <fpage>3397</fpage>
        <lpage>407</lpage>
        <?supplied-pmid 15257284?>
        <pub-id pub-id-type="pmid">15257284</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Girardini</surname>
            <given-names>JE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Pin1/mutant p53 axis promotes aggressiveness in breast cancer</article-title>
        <source>Cancer Cell</source>
        <year>2011</year>
        <volume>20</volume>
        <fpage>79</fpage>
        <lpage>91</lpage>
        <?supplied-pmid 21741598?>
        <pub-id pub-id-type="pmid">21741598</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Marakovits</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Greasley</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dagostino</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ferre</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Humphries</surname>
            <given-names>PS</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Paderes</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Piraino</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kraynov</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>BW</given-names>
          </name>
        </person-group>
        <article-title>Structure-based design of novel human Pin1 inhibitors (III): optimizing affinity beyond the phosphate recognition pocket</article-title>
        <source>Bioorg Med Chem Lett</source>
        <year>2014</year>
        <volume>24</volume>
        <fpage>4187</fpage>
        <lpage>91</lpage>
        <?supplied-pmid 25091930?>
        <pub-id pub-id-type="pmid">25091930</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pollard-Knight</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cornish-Bowden</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Mechanism of liver glucokinase</article-title>
        <source>Mol Cell Biochem</source>
        <year>1982</year>
        <volume>44</volume>
        <fpage>71</fpage>
        <lpage>80</lpage>
        <?supplied-pmid 7048063?>
        <pub-id pub-id-type="pmid">7048063</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lunt</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Vander Heiden</surname>
            <given-names>MG</given-names>
          </name>
        </person-group>
        <article-title>Aerobic glycolysis: meeting the metabolic requirements of cell proliferation</article-title>
        <source>Ann Rev Cell Dev Biol</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>441</fpage>
        <lpage>464</lpage>
        <pub-id pub-id-type="pmid">21985671</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pastorino</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Hoek</surname>
            <given-names>JB</given-names>
          </name>
        </person-group>
        <article-title>Hexokinase II: the integration of energy metabolism and control of apoptosis</article-title>
        <source>Curr Med Chem</source>
        <year>2003</year>
        <volume>10</volume>
        <fpage>1535</fpage>
        <lpage>1551</lpage>
        <?supplied-pmid 12871125?>
        <pub-id pub-id-type="pmid">12871125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mathupala</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Ko</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Pedersen</surname>
            <given-names>PL</given-names>
          </name>
        </person-group>
        <article-title>Seminars in cancer biology</article-title>
        <source>Semin Cancer Biol</source>
        <year>2009</year>
        <volume>19</volume>
        <fpage>17</fpage>
        <lpage>24</lpage>
        <?supplied-pmid 19101634?>
        <pub-id pub-id-type="pmid">19101634</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Feron</surname>
            <given-names>O</given-names>
          </name>
        </person-group>
        <article-title>Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells</article-title>
        <source>Radiothe Oncol</source>
        <year>2009</year>
        <volume>92</volume>
        <fpage>329</fpage>
        <lpage>333</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pavlova</surname>
            <given-names>NN</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>CB</given-names>
          </name>
        </person-group>
        <article-title>The emerging hallmarks of cancer metabolism</article-title>
        <source>Cell Metab</source>
        <year>2016</year>
        <volume>23</volume>
        <fpage>27</fpage>
        <lpage>47</lpage>
        <?supplied-pmid 26771115?>
        <pub-id pub-id-type="pmid">26771115</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Phan</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Yeung</surname>
            <given-names>S-CJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>M-H</given-names>
          </name>
        </person-group>
        <article-title>Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies</article-title>
        <source>Cancer Biology Med</source>
        <year>2014</year>
        <volume>11</volume>
        <fpage>1</fpage>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vander Heiden</surname>
            <given-names>MG</given-names>
          </name>
        </person-group>
        <article-title>Targeting cancer metabolism: a therapeutic window opens</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2011</year>
        <volume>10</volume>
        <fpage>671</fpage>
        <lpage>684</lpage>
        <?supplied-pmid 21878982?>
        <pub-id pub-id-type="pmid">21878982</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Teicher</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Linehan</surname>
            <given-names>WM</given-names>
          </name>
          <name>
            <surname>Helman</surname>
            <given-names>LJ</given-names>
          </name>
        </person-group>
        <article-title>Targeting cancer metabolism</article-title>
        <source>Clin Cancer Res</source>
        <year>2012</year>
        <volume>18</volume>
        <fpage>5537</fpage>
        <lpage>5545</lpage>
        <?supplied-pmid 23071355?>
        <pub-id pub-id-type="pmid">23071355</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Denko</surname>
            <given-names>NC</given-names>
          </name>
        </person-group>
        <article-title>Hypoxia, HIF1 and glucose metabolism in the solid tumour</article-title>
        <source>Nat Rev Cancer</source>
        <year>2008</year>
        <volume>8</volume>
        <fpage>705</fpage>
        <lpage>713</lpage>
        <?supplied-pmid 19143055?>
        <pub-id pub-id-type="pmid">19143055</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liberti</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Locasale</surname>
            <given-names>JW</given-names>
          </name>
        </person-group>
        <article-title>The Warburg effect: how does it benefit cancer cells?</article-title>
        <source>Trends Biochem Sci</source>
        <year>2016</year>
        <volume>41</volume>
        <fpage>211</fpage>
        <lpage>218</lpage>
        <?supplied-pmid 26778478?>
        <pub-id pub-id-type="pmid">26778478</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mathupala</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Rempel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pedersen</surname>
            <given-names>PL</given-names>
          </name>
        </person-group>
        <article-title>Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase</article-title>
        <source>J Bioenergetics Biomembranes</source>
        <year>1997</year>
        <volume>29</volume>
        <fpage>339</fpage>
        <lpage>343</lpage>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pelicano</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Glycolysis inhibition for anticancer treatment</article-title>
        <source>Oncogene</source>
        <year>2006</year>
        <volume>25</volume>
        <fpage>4633</fpage>
        <lpage>4646</lpage>
        <?supplied-pmid 16892078?>
        <pub-id pub-id-type="pmid">16892078</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bao</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>New natural inhibitors of hexokinase 2 (HK2): steroids from Ganoderma sinense</article-title>
        <source>Fitoterapia</source>
        <year>2018</year>
        <volume>125</volume>
        <fpage>123</fpage>
        <lpage>129</lpage>
        <?supplied-pmid 29305912?>
        <pub-id pub-id-type="pmid">29305912</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Granchi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Fancelli</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Minutolo</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>An update on therapeutic opportunities offered by cancer glycolytic metabolism</article-title>
        <source>Bioorganic Med Chem Lett</source>
        <year>2014</year>
        <volume>24</volume>
        <fpage>4915</fpage>
        <lpage>4925</lpage>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schulz</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Tedesco</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Erhard</surname>
            <given-names>KF</given-names>
          </name>
          <name>
            <surname>Mack</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Raha</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rendina</surname>
            <given-names>AR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of a novel 2, 6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors</article-title>
        <source>ACS Med Chem Lett</source>
        <year>2016</year>
        <volume>7</volume>
        <fpage>217</fpage>
        <lpage>222</lpage>
        <?supplied-pmid 26985301?>
        <pub-id pub-id-type="pmid">26985301</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hampton</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hai</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Kappler</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Chawla</surname>
            <given-names>RR</given-names>
          </name>
        </person-group>
        <article-title>Species-and isozyme-specific enzyme inhibitors. 6. synthesis and evaluation of two-substrate condensation products as inhibitors of hexokinases and thymidine kinases</article-title>
        <source>J Med Chem</source>
        <year>1982</year>
        <volume>25</volume>
        <fpage>801</fpage>
        <lpage>805</lpage>
        <?supplied-pmid 7108896?>
        <pub-id pub-id-type="pmid">7108896</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hampton</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Picker</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nealy</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Maeda</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species-or isozyme-specific enzyme inactivators. 4. Interactions of adenosine 5’-triphosphate derivatives with adenylate kinases from <italic>Escherichia coli</italic> and rat tissues</article-title>
        <source>J Med Chem.</source>
        <year>1982</year>
        <volume>25</volume>
        <fpage>382</fpage>
        <lpage>386</lpage>
        <?supplied-pmid 6279845?>
        <pub-id pub-id-type="pmid">6279845</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yamaguchi</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Janssen</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Perkins</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ellisman</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kitada</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reed</surname>
            <given-names>JC</given-names>
          </name>
        </person-group>
        <article-title>Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy</article-title>
        <source>PloS One</source>
        <year>2011</year>
        <volume>6</volume>
        <fpage>e24102</fpage>
        <?supplied-pmid 21949692?>
        <pub-id pub-id-type="pmid">21949692</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>XD</given-names>
          </name>
          <name>
            <surname>Deslandes</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Villedieu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Poulain</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Duval</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gauduchon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Icard</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro</article-title>
        <source>Anticancer Res</source>
        <year>2006</year>
        <volume>26</volume>
        <fpage>3561</fpage>
        <lpage>3566</lpage>
        <?supplied-pmid 17094483?>
        <pub-id pub-id-type="pmid">17094483</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aft</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Welch</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>Enhancing targeted radiotherapy by copper (II) diacetyl-bis (N4-methylthiosemicarbazone) using 2-deoxy-D-glucose</article-title>
        <source>Cancer Res</source>
        <year>2003</year>
        <volume>63</volume>
        <fpage>5496</fpage>
        <lpage>5504</lpage>
        <?supplied-pmid 14500386?>
        <pub-id pub-id-type="pmid">14500386</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <mixed-citation publication-type="other">Maher JC (2006) Treatment of tumor cells with the glycolytic inhibitor, 2-deoxy-D-glucose: effects and mechanisms of resistance. Ph.D. Thesis, University of Miami</mixed-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy</article-title>
        <source>Cancer Lett</source>
        <year>2014</year>
        <volume>355</volume>
        <fpage>176</fpage>
        <lpage>183</lpage>
        <?supplied-pmid 25218591?>
        <pub-id pub-id-type="pmid">25218591</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morrow</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>De Carli</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>The correlation of resistance to 2-deoxyglucose with alkaline phosphatase levels in a human cell line</article-title>
        <source>Exp Cell Res</source>
        <year>1967</year>
        <volume>47</volume>
        <fpage>1</fpage>
        <lpage>11</lpage>
        <?supplied-pmid 6038802?>
        <pub-id pub-id-type="pmid">6038802</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Defenouillère</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Verraes</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Laussel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Friedrich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schacherer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Léon</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The induction of HAD-like phosphatases by multiple signaling pathways confers resistance to the metabolic inhibitor 2-deoxyglucose</article-title>
        <source>Science Signal</source>
        <year>2019</year>
        <volume>12</volume>
        <fpage>eaaw8000</fpage>
      </element-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Jeyamohan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dvorzhinski</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gounder</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bray</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Eddy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Goodin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>DiPaola</surname>
            <given-names>RS</given-names>
          </name>
        </person-group>
        <article-title>Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies</article-title>
        <source>Prostate</source>
        <year>2010</year>
        <volume>70</volume>
        <fpage>1388</fpage>
        <lpage>1394</lpage>
        <?supplied-pmid 20687211?>
        <pub-id pub-id-type="pmid">20687211</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>13732</fpage>
        <?supplied-pmid 28054552?>
        <pub-id pub-id-type="pmid">28054552</pub-id>
      </element-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Anderson</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Stenkamp</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Steitz</surname>
            <given-names>TA</given-names>
          </name>
        </person-group>
        <article-title>Sequencing a protein by X-ray crystallography: II. Refinement of yeast hexokinase B Co-ordinates and sequence at 2.1 Å resolution</article-title>
        <source>J Mol Biol</source>
        <year>1978</year>
        <volume>123</volume>
        <fpage>15</fpage>
        <lpage>33</lpage>
        <?supplied-pmid 355643?>
        <pub-id pub-id-type="pmid">355643</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kuser</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Cupri</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bleicher</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Polikarpov</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Crystal structure of yeast hexokinase PI in complex with glucose: A classical “induced fit” example revised, Proteins: Structure</article-title>
        <source>Function Bioinform</source>
        <year>2008</year>
        <volume>72</volume>
        <fpage>731</fpage>
        <lpage>740</lpage>
      </element-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dawicki-McKenna</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Langelier</surname>
            <given-names>M-F</given-names>
          </name>
          <name>
            <surname>DeNizio</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Riccio</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Karch</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>McCauley</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Steffen</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Pascal</surname>
            <given-names>JM</given-names>
          </name>
        </person-group>
        <article-title>PARP-1 activation requires local unfolding of an autoinhibitory domain</article-title>
        <source>Mol Cell</source>
        <year>2015</year>
        <volume>60</volume>
        <fpage>755</fpage>
        <lpage>768</lpage>
        <?supplied-pmid 26626480?>
        <pub-id pub-id-type="pmid">26626480</pub-id>
      </element-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer</article-title>
        <source>Sci Rep</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>3</fpage>
        <?supplied-pmid 28442756?>
        <pub-id pub-id-type="pmid">28442756</pub-id>
      </element-citation>
    </ref>
    <ref id="CR77">
      <label>77.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Repasky</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Shelley</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Friesner</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Flexible ligand docking with Glide</article-title>
        <source>Curr Protocols Bioinform</source>
        <year>2007</year>
        <volume>18</volume>
        <fpage>8</fpage>
        <lpage>12</lpage>
      </element-citation>
    </ref>
    <ref id="CR78">
      <label>78.</label>
      <mixed-citation publication-type="other">Schrödinger. <ext-link ext-link-type="uri" xlink:href="https://www.schrodinger.com/documentation">https://www.schrodinger.com/documentation</ext-link>. Accessed 30 Oct 2020</mixed-citation>
    </ref>
    <ref id="CR79">
      <label>79.</label>
      <mixed-citation publication-type="other">Schrödinger. <ext-link ext-link-type="uri" xlink:href="https://www.schrodinger.com/kb/186">https://www.schrodinger.com/kb/186</ext-link>. Accessed 20 June 2020</mixed-citation>
    </ref>
    <ref id="CR80">
      <label>80.</label>
      <mixed-citation publication-type="other">OpenEye Scientific Software. <ext-link ext-link-type="uri" xlink:href="https://docs.eyesopen.com/applications/oedocking/">https://docs.eyesopen.com/applications/oedocking/</ext-link>. Accessed 30 Oct 2020</mixed-citation>
    </ref>
    <ref id="CR81">
      <label>81.</label>
      <mixed-citation publication-type="other">OpenEye Scientific Software. <ext-link ext-link-type="uri" xlink:href="https://docs.eyesopen.com/applications/oedocking/make_receptor/make_receptor_setup.html">https://docs.eyesopen.com/applications/oedocking/make_receptor/make_receptor_setup.html</ext-link>. Accessed 22 June 2020</mixed-citation>
    </ref>
  </ref-list>
</back>
